Can a new injection ease heart and lung strain in obesity?

NCT ID NCT07123779

First seen Aug 17, 2026 ยท Last updated Aug 17, 2026

Summary

This trial is testing an experimental drug called HS235 in obese adults who have both pulmonary hypertension and heart failure with preserved ejection fraction. The study aims to see if the drug is safe, how it moves through the body, and whether it can improve heart and lung function. Participants will receive either HS235 or a placebo as a subcutaneous injection, and researchers will monitor for side effects and measure the drug's effects.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
HS235, an experimental biologic given as a subcutaneous injection
What this could lead to
If successful, HS235 could offer a new treatment option for obese people with pulmonary hypertension and heart failure with preserved ejection fraction, potentially improving symptoms and quality of life.
What could go wrong
This is an early-phase trial, so the drug may not work as hoped or could cause side effects. Results from a small group may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH PRESERVED EJECTION FRACTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Investigational Site-101

    RECRUITING

    Greenville, South Carolina, 29605, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.